| Font Size |
In a public announcement made to shareholders, Daiichi Sankyo said the revised schedule for the open offer of Rs 6,818.65 crore for a 20 per cent stake in Ranbaxy would be announced separately.
The offer was originally scheduled to open on August 8 and close on August 27.
This comes amid Ranbaxy's allegations that some multinationals and a leading Indian company are trying to bring down its scrip prices by spreading confusion and speculation.
Earlier on June 16, the Japanese firm, which is acquiring promoters' 34.8 per cent stake in Ranbaxy, had made an open offer for acquiring up to 9.21 crore shares, representing 20 per cent stake in Ranbaxy at a price of Rs 737 each.
The public announcement further said, "The revised schedule of activities in respect of the offer pertaining to acquisition of the equity shares of Ranbaxy Laboratories Ltd will be announced separately after receiving SEBI's observations."
On completion of the acquisition, the board of directors would be re-constituted to comprise 10 members, of which a combination of four independent and non-independent directors would be nominated by Ranbaxy, while the rest six would be named by Daiichi Sankyo.
Discuss this story on expressindia forums
|
|